Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Bates, David ^a,b   Abraham, Suraj ^a   Campbell, Michael ^a,b   Zehbe, Ingeborg ^a,b   Curiel, Laura ^a,b  

^a Thunder Bay Regional Research Institute   (Canada)

^b LAKEHEAD UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANAMIDE; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RHODAMINE; RHODAMINE B;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CONJUGATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LNCAP CELL LINE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PROSTATE CANCER CELL LINE; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; DISEASE COURSE; IMMUNOLOGY; MALE; METASTASIS; MOUSE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; STAINING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE PROGRESSION; FERRIC COMPOUNDS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RHODAMINES; STAINING AND LABELING;

EID: 84901269978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097220     Document Type: Article

References (48)

1. [Anonymous]. Canadian cancer registry (CCR). 2010.
2. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23: 6556-6560. (Pubitemid 46190248)
3. Wang R, Wood DP, Jr, Hollenbeck BK, Li AY, He C, et al. (2011) Risk factors and quality of life for post-prostatectomy vesicourethral anastomotic stenosis. Urology 79:449-457.
4. Nogueira L, Corradi R, Eastham JA (2010) Other biomarkers for detecting prostate cancer. BJU Int 105: 166-169.
5. Ahmad S, Casey G, Cronin M, Rajendran S, Sweeney P, et al. (2011) Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. J Urol 186: 687-693.
6. Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO (2011) Prostate cancer targeting motifs: Expression of alpha(nu) beta(3), neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate 74:689-701.
7. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, et al. (2011) Prostate cancer cell lines under hypoxia exhibit greater stem-like properties PLoS One 6: e29170.
8. Oosterwijk E, Divgi C, Bander NH (2007) Active and passive immunotherapy: Vaccines and antibodies. BJU Int 99: 1301-1304. (Pubitemid 46624179)
9. Bander NH (2006) Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3: 216-225.
10. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH (2004) Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 58: 145-155. (Pubitemid 38160901)
11. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, et al. (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170: 1717-1721. (Pubitemid 37254913)
12. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, et al. (2003) Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 30: 667-676.
13. Bayes M, Rabasseda X, Prous JR (2007) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29: 547-583. (Pubitemid 350260415)
14. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, et al. (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23: 4591-4601. (Pubitemid 46224061)
15. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, et al. (2003) Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol 170: S84-8; discussion S88-9.
16. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, et al. (2003) Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 44: 610-617. (Pubitemid 40003748)
17. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, et al. (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60: 5237-5243.
18. Conway RE, Petrovic N, Li Z, Heston W, Wu D, et al. (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26: 5310-5324. (Pubitemid 44036201)
19. Artemov D (2003) Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 90: 518-524.
20. Artemov D, Mori N, Okollie B, Bhujwalla ZM (2003) MR molecular imaging of the her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49: 403-408. (Pubitemid 36262806)
21. Shahbazi-Gahrouei D, Rizvi SM, Williams MA, Allen BJ (2002) In vitro studies of gadolinium-DTPA conjugated with monoclonal antibodies as cancer-specific magnetic resonance imaging contrast agents. Australas Phys Eng Sci Med 25: 31-38. (Pubitemid 34464222)
22. Shahbazi-Gahrouei D, Williams M, Rizvi S, Allen BJ (2001) In vivo studies of gd-DTPA-monoclonal antibody and gd-porphyrins: Potential magnetic resonance imaging contrast agents for melanoma. J Magn Reson Imaging 14: 169-174. (Pubitemid 32709477)
23. Konda SD, Aref M, Brechbiel M, Wiener EC (2000) Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: Work in progress. Invest Radiol 35: 50-57. (Pubitemid 30033607)
24. Matsumura A, Shibata Y, Nakagawa K, Nose T (1994) MRI contrast enhancement by gd-DTPA-monoclonal antibody in 9L glioma rats. Acta Neurochir Suppl (Wien) 60: 356-358.
25. Bulte JW, Hoekstra Y, Kamman RL, Magin RL, Webb AG, et al. (1992) Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetite particles. Magn Reson Med 25: 148-157.
26. Preziosi P, Orlacchio A, Di Giambattista G, Di Renzi P, Bortolotti L, et al. (2003) Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13: 925-930. (Pubitemid 36790583)
27. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM (2001) Noninvasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 7: 1241-1244. (Pubitemid 33063780)
28. McFadden C, Mallett CL, Foster PJ (2011) Labeling of multiple cell lines using a new iron oxide agent for cell tracking by MRI. Contrast Media Mol Imaging 6: 514-522.
29. Tu C, Osborne EA, Louie AY (2011) Activatable T(1) and T(2) magnetic resonance imaging contrast agents. Ann Biomed Eng 39: 1335-1348.
30. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, et al. (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-3634. (Pubitemid 27381196)
31. Rajasekaran AK, Anilkumar G, Christiansen JJ (2005) Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 288: C975-81. (Pubitemid 40559373)
32. Peldschus K, Schultze A, Nollau P, Kaul M, Schumacher U, et al. (2010) Quantitative MR imaging of targeted SPIO particles on the cell surface and comparison to flow cytometry. Magn Reson Imaging 28: 599-606.
33. Richard C, Lanner C, Naryzhny SN, Sherman L, Lee H, et al. (2010) The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 29: 3435-3445.
34. Bernstein MA, King KF, Zhou ZJ (2004) Basic pulse sequences. In: Anonymous Handbook of MRI pulse sequences. Boston: Academic Press. pp. 630-647.
35. Lu Y, Dasog M, Leontowich AF, Scott RW, Paige MF (2010) Fluorescently labeled gold nanoparticles with minimal fluorescence quenching. The Journal of Physical Chemistry C 114: 17446-17454.
36. Sherry AD, Cacheris WP, Kuan KT (1988) Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: Implications for their use as magnetic resonance contrast agents. Magn Reson Med 8: 180-190. (Pubitemid 18259508)
37. Lin MF, Garcia-Arenas R (1994) Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase. Mol Cell Endocrinol 99: R21-4.
38. Gupta S, Wang Y, Ramos-Garcia R, Shevrin D, Nelson JB, et al. (2010) Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate 70: 1575-1585.
39. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52: 1598-1605.
40. Matsuoka T, Shigemura K, Yamamichi F, Fujisawa M, Kawabata M, et al. (2012) Detection of tumor markers in prostate cancer and comparison of sensitivity between real time and nested PCR. Kobe J Med Sci 58: E51-9.
41. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, et al. (2001) Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163. (Pubitemid 32226241)
42. Aoudjit F, Vuori K (2012) Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012: 283181.
43. Niccoli S, Abraham S, Richard C, Zehbe I (2012) The asian-american E6 variant protein of human papillomavirus 16 alone is sufficient to promote immortalization, transformation, and migration of primary human foreskin keratinocytes. J Virol 86: 12384-12396.
44. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, et al. (2012) Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev 41: 2656-2672.
45. Koo H, Huh MS, Sun IC, Yuk SH, Choi K, et al. (2011) In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res 44: 1018-1028.
46. Fang C, Zhang M (2010) Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine. J Control Release 146: 2-5.
47. Kircher MF, Gambhir SS, Grimm J (2011) Noninvasive cell-tracking methods. Nat Rev Clin Oncol 8: 677-688.
48. Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2: 3-44.